Home › Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
 

Keywords :   


Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

2016-08-08 23:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in of results study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.06Eastern North Pacific Tropical Weather Outlook
08.06Atlantic Tropical Weather Outlook
07.06The rise and rise of fashion giant Shein
07.06Tories pledge to 'back drivers' with new law
07.06Labour vows to 'pull up shutters' for small business
07.06USGBC Applauds Final Definition of a Zero Emissions Building
07.06100ml liquid rule reintroduced at some regional airports
07.06Unite union refuses to endorse Labour manifesto
More »